

Please share your phone number so we can contact you to learn about your health complaint.
Calquence (Acalabrutinib) is a targeted therapy used in the treatment of certain types of blood cancers. It belongs to a class of drugs known as BTK inhibitors, which act on cancer cells within the lymphatic system with high precision.
Calquence is part of the Bruton’s Tyrosine Kinase (BTK) inhibitors family, enzymes that play a key role in the growth and survival of certain abnormal blood cells.
In some blood cancers, BTK signaling becomes overactive, leading to uncontrolled cell growth. Calquence works by:
In simple terms:
It targets the internal growth pathway of blood cancer cells.
Calquence (Acalabrutinib) is used in:
May include:
Rarely: complications requiring close medical monitoring.
Calquence (Acalabrutinib) is available through Macrocare’s approved partners.
You can now request and access the medication easily through us.
WhatsApp contact for medication requests:
Click here
Calquence (Acalabrutinib) Calquence (Acalabrutinib) 100 mg is an effective targeted therapy for blood cancers such as CLL and SLL, working by blocking cancer cell signaling and improving disease control.
Medical Disclaimer:
This content is for educational purposes only and does not replace professional medical advice. Treatment decisions should always be made by a qualified physician.